ADVISORY, Aug. 02, 2017 --
What:
Ion Energy Group, a portfolio company of leading independent interdealer broker OTC Global Holdings and premier broker in natural gas options, NGL, electricity, crude & products and petrochemicals, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Sid Perkins, Founder & Managing Partner, will ring the Closing Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Thursday, August 3, 2017 – 3:45 p.m. to 4:00 p.m. ET
Ion Energy Group Contact:
Brittney Garneau
(713) 627-2223
[email protected]
Nasdaq MarketSite:
Emily Pan
(646) 441-5120
[email protected]
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/
Webcast:
A live stream of the Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.
About Ion Energy Group
Founded in 2008 and based in New York and Houston, Ion Energy is a portfolio company of OTC Global Holdings and a brokering group of EOX Holdings that offers clients brokering services and expertise in natural gas liquids (NGL), product options and the natural gas and crude markets.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit: http://business.nasdaq.com
-NDAQA-


Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Italy Fines Apple €98.6 Million Over App Store Dominance
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



